CN1309392C

CN1309392C - Hyaluronic acid mediated adenoviral transduction

Info

Publication number: CN1309392C
Application number: CNB038071819A
Authority: CN
Inventors: S·R·昌德胡里; R·L·赫特维茨; M·Y·赫维茨; V·赫尔科比; K·T·马库斯
Original assignee: RESEARCH DEVELOPMENT FOUDATION
Current assignee: RESEARCH DEVELOPMENT FOUDATION; Research Development Foundation
Priority date: 2002-02-15
Filing date: 2003-02-14
Publication date: 2007-04-11
Anticipated expiration: 2023-02-14
Also published as: EP1480656A4; AU2003213074A1; WO2003070256A1; JP2005531502A; US20070148734A1; US7144870B2; CN1642560A; EP1480656A1; CA2476451A1; US20030186936A1

Abstract

The present invention provides methods of treatment of adenoviral mediated disease, improved methods for transducing cells with adenoviral and related vectors, and improved methods of gene therapy utilizing such methods.

Description

The adenovirus transduction of hyaluronic acid mediation

Background of invention

The application requires the rights and interests of No. the 60/357th, 485, the U.S. Provisional Patent Application series submitted on February 15th, 2002, and it is for referencial use that all the elements of this application are included this paper in.

Invention field

The present invention relates to molecular biology, gene therapy and virus disease treatment field.Clearer and more definite says, the present invention relates to treat the method for adenovirus infection and disease, relates to improving one's methods and use the method for this method improvement gene therapy (effect) with the transgene expression in adenovirus and the relevant carriers transfered cell.

The description of relevant speciality

Wild-type adenovirus is relevant with many kinds of human diseasess, comprises respiratory tract, eyes and gastrointestinal infection.These infection be child school absent from school and adult disability main cause.In the individuality of immunity infringement, adenovirus infection also there is not effective antiviral therapy at present, normally fatal.Therefore, perhaps adenovirus infection is fatal for accepting chemotherapy, bone marrow transplantation, other organ transplantations or suffering from the immunity infringement patient of AIDS.The special susceptible of children's bone marrow transplant patient has 10-30% that adenovirus infection takes place.

Be not highly resistant to the antiviral compound of adenovirus infection.Therefore, a kind of effective ways for the treatment of adenovirus infection need be developed in this field, especially the individuality that damages for immunity.

By contrast, nothing-pathogenic replication defective sexual gland virus carrier can be used for many clinical preceding and clinical gene therapy.The human gene therapy is a kind of method of treatment human diseases, and its basis is the gene expression of modifying in patient's cell.In the past decade, having become is apparent that, as the obstacle the most remarkable that the gene therapy of treatment hereditary, cancer and other hereditary dysfunction strategies is succeedd, is the useful gene transfer of (needs) exploitation and the carrier of expression.The carrier that eucaryon sexually transmitted disease (STD) poison has been treated as human body gene.The viral vector that is generally used for gene therapy research is an adenovirus.

Modify do not have a replication capacity therefore do not have pathogenic adenovirus, just in many metabolism and tumor disease, be used as the carrier of delivering therapeutic gene.These adenovirus vectors may particularly suitable disease, the cancer that preferably can treat for example by instantaneous therapeutic gene expression, because DNA needn't be integrated into host genome, and the expression of render transgenic is limited.Adenovirus vector also is significant especially in the gene substitution treatment, and wherein heredity or metabolic deficiency or shortage can be corrected by alternative expression of gene is provided, and the product of this alternative gene code can be corrected this kind defective or shortage.

Can modify adenovirus and therapeutic or report transgenic are effectively flowed to polytype cell.Recombinant adenovirus class 2 types and 5 types (being respectively Ad2 and AdV5) that cause the human breathing tract disease are to develop those adenoviruss of doing gene therapy at present.Ad2 and AdV5 all belong to the subclass of adenovirus, and be uncorrelated with human malignancies.Recently, developed hybridization adenovirus vector AdV5/F35, and proved its in gene therapy and correlational study, be of great importance (Yotnda etc., 2001).

Recombinant adenovirus can provide the transgenic of high level to carry.This system effect in the delivering therapeutic transgenic in the body of correcting genetic unbalance obtains proof (Watanabe, 1986 in the animal model at various diseases; Tanzawa etc., 1980; Golasten etc., 1983; Ishibashi etc., 1993; And S.Ishibashi etc., 1994).In fact, the coding cystic fibrosis recombinant replication-defective sexual gland virus of striding film regulator (CFTR) cDNA has gone through to use (Wilson, 1993) at least two human CF clinical trials.Hurwitz etc., (1999) have proved the therapeutic effect of adenovirus mediated gene therapy in mice cancer (retinoblastoma) model.

Unfortunately, though adenovirus vector transduction target cell is effective, not necessarily can in target cell and tissue, produce the transgene expression of desirable level.Noticed that within the eye observed high-caliber relatively transgene expression is an exception in the environment.

Therefore need the effectively infection of treatment wild-type adenovirus, especially the infection in immunity infringement individuality.Also need and effectively to improve the method and composition that imports the transgene expression in various kinds of cell type and the tissue.

Summary of the invention

The present invention relates to can be used for the compositions and the method for adenovirus mediated disease and adenovirus infection treatment, and utilize adenovirus and relevant carriers to improve the compositions and the method for the intracellular transgene expression of input.

Therefore, the present invention's one embodiment preferred is a kind of method for the treatment of the adenovirus disease, this method comprises that evaluation need treat the object of adenovirus disease, and gives this object a kind of compositions that contains the adenovirus inhibitor, and the group amount is enough to suppress or prevention adenovirus disease.Another embodiment preferred is a kind of method that suppresses adenovirus infection, and this method comprises and give cell a kind of compositions that contains the adenovirus inhibitor that its consumption is enough to suppress the development of adenovirus infection.

One related embodiment is the method for treatment adenovirus disease, this method comprises that evaluation need treat the object of adenovirus infection, and the compositions of a kind of gland-containing virus inhibitor of the cell that gives this object, its consumption is enough to suppress the development of adenovirus infection, thereby suppresses the infection of adenovirus.Another embodiment preferred is the method for treatment adenovirus disease, and this method comprises the object that evaluation need be treated, and the inhibitor that gives the adenovirus mediated transgene expression of adenovirus vector transducer cell of this object.

One preferred embodiment is a kind of method that suppresses transgene expression, and this method comprises the cell of acquisition with adenovirus or adenovirus vector transduction, and this cell is contacted with the inhibitor of adenovirus-mediation transgene expression.Coffee one preferred aspect, described cell is the part of tissue.Other embodiment preferred comprise that described cell is a vertebrate cells, mammalian cell, those schemes of Primate cell or human cell.What certainly, described cell also can right and wrong-mankind.In particularly preferred embodiments, treatment to as if the people.In other schemes, the object right and wrong-mankind of treatment.

In particularly preferred embodiments, described adenovirus inhibitor comprises low-molecular-weight hyaluronic acid.Think that low-molecular-weight hyaluronic acid is an average molecular weight range from being less than 750,000Da is to hyaluronic lowest molecular weight, for example hyaluronic acid of a recurring unit.Therefore, the mean molecule quantity that it is believed that the low-molecular-weight hyaluronic acid enzyme can be lower than 750,000; 650,000; 550,000; 500,000; 450,000; 400,000; 350,000; 300,000; 250,000; 200,000; 150,000; 100,000; 50,000Da or lower, or any scope that can therefrom reason out.

The other method of considering low-molecular-weight hyaluronic acid in the embodiment of the present invention is the low-molecular-weight hyaluronic acid that shows than the much lower molecular weight of high molecular weight hyaluronic acid.In specific embodiments, when making comparisons by agarose gel electrophoresis, this low-molecular-weight hyaluronic acid shows the molecular weight more much lower than high molecular weight hyaluronic acid.

In other embodiment of the present invention, the hyaluronic catabolite of described adenovirus inhibitor packages pbz polymer amount.These catabolites can obtain by many methods.In one embodiment, described catabolite comprises out of date hyaluronic acid.Out of date hyaluronic acid is defined as out of date hyaluronic acid, and it is unacceptable as clinical compositions or as high-molecular weight hyaluronic acid.This out-of-dately provide on the hyaluronic acid commercial sample by maker usually, but also available normal experiment is determined.Similar, in another embodiment, described inhibitor comprises Vitrea catabolite.In a kind of such embodiment, this catabolite is out of date vitreous body.

In other embodiments, described adenovirus inhibitor comprises the product of handling the high molecular weight hyaluronic acid acquisition with lyases or hyaluronidase.Similar, in one embodiment, described inhibitor comprises the vitreous body of handling with lyases or hyaluronidase.

In other preferred embodiment, the cell that will handle is cultivated in containing the solution of this inhibitor.In its specific embodiments, described inhibitor is low-molecular-weight hyaluronic acid.The concentration range of low-molecular-weight hyaluronic acid can from about 30mg/100ml solution to more than the 240mg/100ml.Therefore, the concentration of low-molecular-weight hyaluronic acid can be 30mg/100ml, 60mg/100ml, 120mg/100ml or 240mg/100ml or any concentration that therefrom can reason out.In addition, in specific embodiments, the concentration of low-molecular-weight hyaluronic acid can be near saturated.

Because scope of the present invention comprises the method and composition that improves adenovirus mediated transgene expression, one preferred embodiment is to improve the method for transit cell gene expression, and this method comprises that acquisition is with the cell of adenovirus vector transduction and this cell is contacted with the reinforcing agent of adenovirus mediated transgene expression.

In certain embodiments, can make in the time range of described cell 2-20 hour or any therefrom inference after transduction and contact with reinforcing agent.Embodiment preferred comprises makes described cell 2-4,6 or 8 hours or wherein any shorter time after transduction, contacts with this reinforcing agent.In certain embodiments, described cell is contacted after 2 hours with reinforcing agent in transduction.Certainly, in some other embodiments, described cell is contacted basically in transduction with reinforcing agent.In other embodiment preferred, make described cell continue to contact with reinforcing agent from transduction.

In the preferred embodiment of the invention relevant with adenovirus mediated transgene expression enhancing, described reinforcing agent comprises vitreous body, high molecular weight hyaluronic acid, or their mixture.In specific embodiments, described reinforcing agent comprises low-molecular-weight hyaluronic acid associating vitreous body.In other specific embodiments, described reinforcing agent is a vitreous body.In some other preferred embodiments, described reinforcing agent is high-molecular weight hyaluronic acid.

Preferred related embodiment comprises the step that the cell of adenovirus or adenovirus vector transduction is cultivated in containing the compositions of reinforcing agent.When reinforcing agent was vitreous body, the concrete scheme of executing comprised vitreous body concentration those schemes between 0.5%-5% (v/v) scope in the compositions.Specific embodiments comprises that the vitreous body concentration in the compositions approximately is those schemes of 0.5%, 2.5% or 5%.

In other preferred embodiments, described reinforcing agent comprises high-molecular weight hyaluronic acid.It is hyaluronic average molecular weight range from greater than 750 that the molecular weight of high molecular weight hyaluronic acid is considered, 000Da for example surpasses millions of Da or bigger to hyaluronic highest weight.Therefore, the mean molecule quantity of consideration high molecular weight hyaluronic acid can be greater than 650,000; 750,000; 1,000,000Da or higher, or the scope of any therefrom inference.

In embodiments of the invention, the other method of the high molecular weight hyaluronic acid of being considered is that this high molecular weight hyaluronic acid shows the molecular weight more much higher than low-molecular-weight hyaluronic acid.In specific embodiments, when making comparisons by agargel electrophoresis, described high-molecular weight hyaluronic acid shows the molecular weight that is much higher than low-molecular-weight hyaluronic acid.

When described reinforcing agent was high molecular weight hyaluronic acid, the concentration range that some embodiment is included in high molecular weight hyaluronic acid in the compositions of cell incubation was from 10 micrograms/more than 100 microlitre to 100 micrograms/100 microlitres.

Embodiment of the present invention are not subjected to the used concrete adenovirus or the restriction of adenovirus vector.The inventor has found a kind of method, can strengthen or suppress the common caused transgene expression of adenovirus infection and this adenovirus and carrier.Certainly, in specific embodiments, be that described reinforcing agent is contacted with the cell of adenovirus infection.In other specific embodiments, consider that described adenovirus vector is derived from adenovirus 5 types or adenovirus 2 types and their relative.Certainly, when the adenovirus construction thing was formulated into carrier, can comprise can be at the transgenic of cell inner expression.

Consideration can strengthen or suppress the concrete transgenic of its expression by method and composition of the present invention, and they include but not limited to applied transgenic in treatment of cancer.In other specific embodiments, described transgenic is retinoblastoma (RB) gene or thymidine kinase (TK) gene.In other embodiments, described transgenic is a tumor suppressor gene.In specific embodiments, described tumor suppressor gene coding p53.In other embodiment preferred, described transgenes encoding-reporter gene.Reporter gene is that this professional and technical personnel knows, and the selection of reporter gene is not limited to the present invention (used).Embodiment comprises that transgenic is luciferase, green fluorescent protein matter, or those schemes of beta-galactosidase gene.

The invention provides the enhancing of the transgene expression of adenovirus-mediation in the cell.In specific embodiments, described cell is an a kind of part of tissue.In other embodiments, described cell is a vertebrate cells, mammalian cell, Primate cell or human cell.

The inventor finds that also CD44 protein regulates the effect of transgene expression when hyaluronic acid or vitreous body exist.Therefore, an embodiment is a kind of method of regulating transgene expression, and this method comprises makes cells transfected contact with adenovirus vector and at least a anti-CD44 specific antibody.The step that relevant embodiment comprises is for before making described cell and at least a anti-CD44 specific antibody contacting, when contacting or contact with high molecular weight hyaluronic acid or vitreous body afterwards.In certain embodiments, described antibody comprises at least a monoclonal antibody.In other embodiments, described antibody is KM114.

Other embodiment of the present invention comprises a kind of test kit that increases transgene expression, and it comprises high molecular weight hyaluronic acid or vitreous body, and the component that is used for the adenovirus vector transfection.

Other embodiment comprises the method for screening hyaluronic acid form.Known to those technical staff of this specialty, hyaluronic form can according to their chemical constitution, chemical characteristic, physical characteristic and herein they to the effect classification of the transgene expression of adenovirus-mediation.The limiting examples of these forms is high molecular weight hyaluronic acid, low-molecular-weight hyaluronic acid, can effectively suppresses the hyaluronic acid of the transgene expression of adenovirus-mediation, with the hyaluronic acid that can effectively strengthen the transgene expression of adenovirus-mediation, and the hyaluronic acid that can effectively treat the adenovirus disease.

Therefore; Some embodiment comprises acquisition hyaluronic first sample (a); Obtain hyaluronic second sample of form known (b); And relatively the sample that obtains in (a) with (b) in the sample that obtains to the effect of adenovirus mediated transgene expression, wherein strengthened transgene expression and shown it is the hyaluronic acid of expressing enhanced form, suppressed transgene expression and shown it is the hyaluronic acid of expression inhibiting form.Similar, some embodiment comprises by gel electrophoresis comparative sample (a) and step (b), and the step that the electrophoretic mobility of sample (a) and (b) is relevant to adenovirus mediated transgene expression effect with them.Particularly preferred embodiment comprises agarose gel electrophoresis.

Abide by secular patent clause, word in claims and description " a " and " an ", when and word " comprise " when using together, represent one or more.

Brief description of drawings

Following accompanying drawing has been formed the part of this description, and comprises in this manual further to illustrate some aspect of the present invention.Can better understand the present invention by the detailed description of the specific embodiments that provides and the one or more figure that unite with reference to these accompanying drawings here.

Fig. 1. vitreous body has increased adenovirus mediated transgene expression.Rectangular histogram is represented the standard error of meansigma methods.

Fig. 2. hyaluronate lyase has been eliminated the enhanced adenovirus mediated transgene expression of vitreous body.

Fig. 3. enhanced transgene expression does not rely on the combination or the internalization of adenovirus.

Fig. 4 A, 4B, 4C and 4D.Vitreous body has strengthened with adenovirus mediated transgene expression in the cell of another kind of adenovirus receptor transduction.With WERI-Rb cell (1 * 10 ⁴Cells/well) cultivates in not having the medium of serum, contain that (C D) or not contains (A, B) 0.5% vitreous body.Described cell is transduceed with the ratio of 5vp/ cell with chimeric adenovirus (AdV5/F35), and the fiber of AdV35/ball-joint domain has substituted fiber/ball-joint domain of AdV5 in this chimeric adenoviral.Shown representative area bright district (A, C) and phosphor region (B, D) figure.

Fig. 5. the transgene expression of vitreous body mediation strengthens; The time dependence that vitreous body adds.Reference line has shown the baseline transgene expression when lacking vitreous body.

Fig. 6. the transgene expression of vitreous body mediation strengthens; The time dependence that vitreous body adds.Reference line is illustrated in whole 20 hour nurturing period Continuous Contact 0.5% Vitrea transit cell expression of gene.

Fig. 7. hyaluronic acid activates adenovirus mediated transgene expression.Rectangular histogram is represented the standard error of meansigma methods.

Fig. 8. the hyaluronic acid of " discarding " suppresses adenovirus mediated transgene expression.Rectangular histogram is represented the standard error of meansigma methods.

The activated CD44 of Fig. 9 .PMA-is very important for strengthening adenovirus mediated transgene expression.Whether rectangular histogram is represented the standard error of meansigma methods, measure meaningful with pairing Student t check.

Figure 10. anti-CD-44 has suppressed adenovirus mediated transgene expression.Rectangular histogram is represented the standard error of meansigma methods.

Figure 11. the vitreous body that boils is for the effect that strengthens adenovirus mediated transgene expression.

Figure 12. bonded vitreous body and low-molecular-weight hyaluronic acid are to strengthening the effect of adenovirus mediated transgene expression.

Figure 13. vitreous body is to the effect of transgene expression adenovirus mediated in people's conjunctiva explant.

Figure 14. the hyaluronic lyases digestion of high molecular (HMW).

Figure 15. the hyaluronidase of lyases digestion is to the effect of adenovirus mediated transgene expression.

Detailed Description Of The Invention

The inventor is surprised to find, a kind of important component of eye vitreous, and hyaluronic acid can be regulated and pass through adenopathy The genetically modified expression of poisonous carrier transfered cell and the infectiousness of wild-type adenovirus. The inventor is surprised to find, The hyaluronic acid of HMW itself or as Vitrea a kind of composition pass through adenopathy with external can the enhancing in vivo Poisonous carrier is from the functional genetically modified expression of eye external environment transfered cell. The enhancing of this expression does not rely on adenopathy Poisonous carrier adheres to and enters cell.

More wondrous and meaningfully, the inventor find low-molecular-weight hyaluronic acid can suppress adenovirus infection and The transduction of adenovirus vector. The most meaningfully, low-molecular-weight hyaluronic acid, or by enzymatic reaction or other Process the low-molecular-weight hyaluronic acid through modifying or degrading, all can be used to treat the adenovirus infection disease. Therefore, The hyaluronic acid of low-molecular-weight or modification or vitreum can be used as the preventative or therapeutic combination for the treatment of adenovirus infection Thing.

Inhibitory action refer to a kind of preparation partially or completely stop, limit, slow down, reduce, postpone, reduce, suppress, The compacting or disturb certain biological process, with any degree, partially or completely. Therefore, inhibitor be can the part or Stop fully, limit, slow down, reduce, postpone, retrain, reduce, suppress, suppress or disturb certain biology mistake Journey, biochemical reaction for example, virus or Growth of Cells or other physiology courses include but not limited to infect or disease Sick process, disease or Life Cycles process, the preparation of organ dysfunction or performance etc.

The inventor finds that also hyaluronic acid is by activating activity in a series of cells with the CD44 effect, and CD44 is A member of common adhesion molecule family on many cell types. Therefore, the energy specific binding is in hyaluronic acid The antibody that the hyaluronic acid of CD44 activates is also blocked in the binding function territory, suppressed simultaneously vitreum-enhancing and baseline Adenovirus mediated transgene expression. Can express the Jurkat cell of CD44 through engineering improvement, but not be known Do not express the wild type Jurkat cell of CD44 or any other hyaluronic acid bind receptor, may be presented at existence Can suppress the enhancing of the transgene expression of adenovirus vector conveying when vitreum or high molecular weight hyaluronic acid. Phorbol Ester has strengthened the effect that vitreum produces greatly. Report in the past shows that PMA can cause the oligomerization of CD44 with sharp Live. Can cultivate to produce with lyases the low-molecular-weight hyaluronic acid of (or with hyaluronic acid out-of-date or degraded), Not only can not strengthen adenovirus mediated transgene expression, and amazing and suppressed unexpectedly the baseline gland The transgene expression of viral vectors mediation.

Above-mentioned enhancement effect does not rely on used promoter or transgenosis, but is special to adenovirus vector, namely Make them utilize different associativities or internalization acceptor. The time course prompting hyaluronic acid of this effect is for adenopathy The enhancing that the poison gene transfer is expressed occurs in after viral combination and the internalization.

Report in the past proved HMW hyaluronic acid can in conjunction with and activate the CD44 signal transduction, but low branch Son amount hyaluronic acid can in conjunction with but do not activate identical mechanism. Therefore low-molecular-weight hyaluronic acid has played the CD44 function and has pressed down The effect of preparation. High molecular weight hyaluronic acid has strengthened adenovirus mediated genetically modified expression, yet low-molecular-weight Hyaluronidase has suppressed the baseline adenoviral transduction. The glucuronic acid of the basic unit of formation hyaluronic acid-N-acetyl Portugal Grapes glucosamine disaccharide can activate CD44 but only when endocellular injection. CD44 has the cell function of many complexity, comprises Play the function of cell traffic albumen, control cytoskeletal structure and motility, and by control microtubule and the moving egg of flesh The transhipment of intracellular protein is regulated in white assembling. Anti-by the CD44 modulability cascade that low-molecular-weight G-is protein mediated Should have influence on many these functions.

1. adenovirus

Adenovirus comprises linear dsdna, and genomic size is 30-35kb (Reddy etc., 1998; Morrison Deng, 1997; Chillon etc., 1999). The human adenovirus that has the serotype more than 50 kinds, and 80 kinds with On correlation form, they can be divided into 6 families (Wadell etc., 1980) according to immunity, molecule and profile. On the physics, adenovirus is a kind of medium sized icosahedron viruses, contains a double-stranded linear DNA genome, For example Adenovirus Type 5 has 35,935 base-pairs (Chroboczek etc., 1992). Adenovirus require enters the host Cell and viral genome is transferred to nucleus could infection cell and replication-competent virus.

The notable feature of adenoviral gene group is an early region (E1, E2, E3 and E4 gene), a mesozone Territory (pIX. gene, Iva2 gene), a zone in late period (L1, L2, L3, L4 and L5 gene), a main evening Phase promoter (MLP), inversion-end-duplicate block (ITRs) and psi sequence (Zheng etc., 1999; Robbins Deng, 1998; Graham and Prevec, 1995). Described early gene E1, E2, E3 and E4 after infection from disease Poison is expressed, the polypeptide of its coding can regulate viral gene expression, cytogene expression, virus replication and press down Apoptosis processed. Further during virus infections, MLP is activated, and this has caused the expression of (L) gene in late period, The adenovirus capsidization of the polypeptide of coding is required. Described mesozone encoding adenovirus capsid component. Adenovirus is inverted Terminal duplicate block (ITRs; 100-200bp length), be cis element, play a part replication initiation, be virus Dna replication dna institute is essential. Described psi sequence is that adenoviral gene group packing is necessary.

The mechanism that adenovirus, particularly adenovirus serum 2 types and 5 types infect has been subjected to broad research. Identify A kind of host cell surface protein called after CAR (Ke's Sa Room adenovirus receptor) is the main combination of these adenovirus Acceptor. The cell endogenous function of CAR is not also illustrated. Interaction between fiber ball-joint and the CAR is enough to make gland Virus is bonded to cell surface. Yet, subsequently the penton base of adenovirus and other cell cortex proteins, α_vInteraction between the member of integrin family is that effectively internalization is necessary for virus. Adenovirus (component) Dissociate and during internalization, begin; Celloglobulin is stayed cell surface and is incorporated into CAR, all the other components of adenovirus along with Virion is transported by cytoplasm and is in a step-wise fashion dissociated at formation hole, nuclear membrane place complex. Viral DNA is discharged Enter nuclear by nuclear membrane, viral DNA copies in nuclear, expresses virus protein, is assembled into new virion. Specific step in the adenovirus infection mechanism can be used as the potential target of regulating virus infections and gene expression.

2. the improved adenovirus of genetic engineering and adenovirus vector

In specific embodiments, consider to carry the expression construction with adenovirus expression carrier. " gland virus expression carries Body " or " adenovirus vector " comprise that those are enough to (a) and support the packing of described construction and (b) final express The construction of gland-containing virus sequence has been cloned in tissue or the cell-specific structure. Therefore, adenovirus vector The carrier that can comprise the engineering distribution distribution transformation of any gland-containing virus sequence.

Adenovirus expression carrier of the present invention comprises the genetic engineering modified form of adenovirus. The character of adenovirus vector is not Think successful implementation key of the present invention. Adenovirus can be one of serotype known to any and/or subgroup A-F. In order to obtain to can be used for a kind of viral vectors of gland among the present invention, the Adenovirus Type 5 of subgroup C is preferred parent material. This is because Adenovirus Type 5 is a kind of adenovirus hominis, knows about its large number of biological chemistry and hereditary information, And it has been used in history great majority and has adopted in the structure of adenovirus as carrier.

The advantage that adenoviral gene shifts has; Can infect far-ranging cell type (comprising non-fissility cell), Medium sized genome, simple to operate, high infectious, and they can with high titre propagation (Wilson, 1996). In addition, the adenovirus infection of host cell can not cause chromosomal integration, because adenovirus DH can swim Copy from mode, not the latent gene toxicity relevant with other viral vectors. Adenovirus structurally also is stable (Marienfeld etc., 1999), and after a large amount of amplifications, do not measuring genomic rearrangement (Parks etc., 1997; Bett etc., 1993).

The growth of adenovirus and operation are that this art person knows, and show that host in the wide external and body is arranged Scope (United States Patent (USP) 5,670,488; United States Patent (USP) 5,932,210; United States Patent (USP) 5,824,544). This group virus Can be high titre obtain for example 10⁹-10 ¹¹Plaque forming unit/ml, they have hyperinfection. Adenovirus Life cycle does not need to be integrated in the host cell gene group. The alien gene that adenovirus vector is carried is episome, Therefore be low genotoxicity for host cell.

Although adenovirus vector is compared with other carrier systems several unique advantages are provided, their application is frequent Be subjected to the immunogenicity of carrier, the size constraint that recombination inserts, the low and transgene expression water of levels of replication Flat low restriction. A major concern point of using adenoviral vectors be during carrier produces in package cell line or During the gene therapy individuality, whether produced replication activity virus. The generation of replication activity virus may be to patient Cause the serious threat of the unexpected virus infections that arrives and pathological examination. Armentano etc. have described the replication defective venereal disease Potential feasibility (the United States Patent (USP) that can eliminate the replication activity adenovirus and produce is unintentionally claimed in the preparation of poisonous carrier 5,824, No. 544). The method of this kind replication defective adenoviral comprises deletion E1 zone and replacement protein IX gene, Wherein said carrier can the expressing heterologous mammalian genes.

The common method that a kind of generation can be used as transgenosis carrier adenovirus is deletion E1 gene (E1), and this relates to The inducing of E2, E3 and E4 promoter (Graham and Prevec, 1995). Then the therapeutic gene restructuring is inserted and get For the E1 gene, wherein the expression of therapeutic genes is driven by E1 promoter or allogeneic promoter. Then " auxiliary Hand " propagation E1-replication defective virus in the clone, this auxiliary cell line can provide trans E1 polypeptide (people's embryo for example Tire kidney cell line 293). Perhaps, can delete the E3 zone, part E4 zone or both can be in eukaryotics Heterologous nucleic acid sequence under the promoter control of operation is inserted in the adenoviral gene group, and (U.S. is special to be used for gene delivery Sharp the 5th, 670, No. 488; United States Patent (USP) the 5th, 932, No. 210).

Certainly, in specific embodiments of the present invention, consideration can be with low-molecular-weight or modified hyaluronic acid or glass The glass body is used for treating the replication activity adenovirus of this careless lower generation. As mentioned above, consider that the present invention should adopt Carrier be replication defective. Yet, consider that also the method that contains the replication activity adenovirus vector may lead Cause so-called amplification. Therefore, consider that specific embodiment is, can by use low-molecular-weight or modified thoroughly Phaneroplasm acid or vitreum are regulated amplification degree and the speed of replication activity viral vectors.

(AdV5/F35, for example), they can flow to transgenosis to have produced a class mosaic adenovirus vector Hematopoietic progenitor. Very effective when the AdV5/F35 carrier is transitted to original progenitor with transgenosis (Yotnda etc., 2001). These carriers also can infect the hoechst feminine gender ' secondary group ' of bone marrow cell. Carried by these carriers Immunomodulatory gene can transduce and express about more than 5 days with certain level. In the present invention one preferred enforcement side In the case, with hyaluronic acid process transgenosis by this chimeric adenoviral vectors importing (such as but not limited to AdV5/F35), can fully strengthen genetically modified expression.

3. carry out gene therapy with adenovirus and adenovirus relevant carriers

In certain embodiments, the inventor considers to strengthen with hyaluronic acid or vitreum and related compound and leads Enter the genetically modified expression in the cell, thereby reach gene therapy purpose.

Gene therapy generally includes the transgenosis transfered cell, genetically modified expression of results be alleviate or treated disease or Genetic disease. Included transgenosis can be those coded proteins, structural or ribozyme s, suppress to produce Thing is antisense RNA or DNA for example, or other any gene outcomes. Expression be this gene outcome production process or This gene outcome produces the effect that takes place. Therefore, strengthen to express comprise produce more certain transgene product or Promote this product in the cell that limits, tissue, organ or the effect in the fuselage state. Defeated by adenovirus vector The cell transduction that send transgenosis to comprise to be called as. As used herein, transduction is defined as by adenovirus or relevant carriers With transgenosis or transgenosis construct transfered cell.

Many experiments, new invention, preclinical phase research and clinical testing are at present adopts adenovirus defeated as gene Send the conceptual phase of carrier. For example, developing take the adenoviral gene conveying as the basis gene therapy be used for the treatment of Hepatopathy (Han etc., 1999), mental illness (Lesch, 1999), sacred disease (Smith, 998; Hermens and Verhaagen, 1998), coronary artery disease (Feldman etc., 1996), muscle disease (Petrof, 1998), with And various cancers such as colorectal cancer (Dorai etc., 1999), carcinoma of urinary bladder (Irie etc., 1999), prostate cancer (Mincheff etc., 2000), head and neck cancer (Blackwell etc., 1999), breast cancer (Stewart etc., 1999), lung Cancer (Batra etc., 1999) and oophoroma (Vanderkwaak etc., 1999). In specific embodiments of the present invention, Adopt high molecular weight hyaluronic acid or vitreum to improve the genetically modified expression that adenovirus vector is carried.

Therefore, target of the present invention can by raising be included in the therapeutic genes in the gene delivery system expression and Realize that this induction system for example is the recombinant adenoviral vector induction system, this system of preparation can make by transducer cell The contact expression facilitator, for example high molecular weight hyaluronic acid or vitreum, and cause the enhancing table of this therapeutic genes Reach.

Describedly can be present in the cell culture or in the body by transducer cell.In vivo, such as considered in the present invention, cell can be arranged in any tissue or the organ of relevant body.Tissue can comprise host cell or cell to be changeed or the cell that contacts with nucleic acid delivering composition and/or other preparations.Described tissue can be the part of body or obtain from its separation.In certain embodiments, tissue and its composition cell can include but not limited to, blood (hematopoietic cell (for example artificial blood progenitor, human hematopoietic stem cell, CD34 for example ⁺Cell, CD4 ⁺Cell), lymphocyte and other blood pedigree cells), bone marrow, brain, stem cell, blood vessel, liver, lung, bone, breast, cartilage, cervix uteri, colon, cornea, embryo, endometrium, endothelium, epithelium, esophagus, fascia, fibroblast, folliculus, ganglionic cell, neurogliocyte, goblet cell, kidney, lymph node, muscle, neuron, ovary, pancreas, peripheral blood vessel, prostate, skin, small intestinal, spleen, stomach, testis.

In certain embodiments, described host cell or tissue pocket are contained at least one body.In certain embodiments, but this body people, Primate or mice.In other embodiments, this body can be any adenovirus and correlated virus or adenovirus vector eukaryote or eukaryotic cell that infect or transduction of being subject to.The person skilled in art can further understand should cultivate above-mentioned host cell under what conditions, thereby preserves them and make their divisions form generation.

Developed the strategies in gene therapy that is used for treatment of cancer.Developed according to the diverse ways of gene rotating method and treated tumor.The method of having developed is corrected the special damage of determined gene loci, and this infringement can make tumor transform and development (Spandidos etc., 1990; Banerjee etc., 1992).Can the employing technology make the overexpression of dominance oncogene to suppress transformed gene or gene outcome.The forfeiture of tumor suppressor gene function can the employing method recovers the function of wild type tumor suppressor gene.Except these realize the method for sudden change compensation, developed genetic technique and come specificity and selectivity to eradicate tumor cell.These molecular chemistry Therapeutic Method depend on specific expressed (Abe etc., 1993) of toxin gene in the tumor cell.At last, gene transfer method has been used to realize the antineoplastic immune inoculation.These heritability immunostimulant methods have adopted hereditary regulation technology, improve the immunity identification to tumor.As a result, developed the gene therapy that multiple distinct methods is realized cancer, all methods all adopt the adenovirus vector transducer cell.

Hurwitz etc. (1999) have described a kind of adenovirus vector that contains simple skin ulcer rash (virus) thymidine kinase gene, when external transduction goes into to use the treatment of prodrug gancyclovir in the Y79Rb human retinoblastoma cell with it, can effectively promote killing and wounding to those retinoblastoma cells.A kind of retinoblastoma mouse model of making by intravitreal injection Y79Rb cell also responds to transduction and treatment.Therefore, gene therapy can effectively reduce the tumor load in the human retinoblastoma mouse model.Obviously, the fragmentation effect that can further increase this therapy is expressed in the genetically modified enhancing of adenovirus vector conveying.Specifically, environment is in the vitreous body within the eye, and it is favourable that the expression of adenovirus vector strengthens.More generally, to be presented in the animal model treatment kinds of tumors be effective to AdV-TK/ gancyclovir suicide gene therapy.See for example Eastham etc., 1996 (prostate); Chen etc., 1994 (brains); Chen etc., 1995 (livers); O ' Malley etc., 1995 and Goebel etc., 1996 (necks); Behbakht etc., 1996 and Rosenfeld etc., 1996 (ovaries); Esandi etc., 1997 (mesotheliomas).Specific embodiments of the present invention comprises (effect) that adopts hyaluronic acid to strengthen or promote the gene therapy of AdV-TK/ gancyclovir.

The concrete transgenic that adenovirus vector is carried comprises that without limits those can be used for various treatments and research purpose transgenic, and reporter gene and reporter gene system and being used for follows the tracks of the construction of transgene expression and adenovirus and adenovirus vector transduction effectiveness.Therefore, as an example, be the possible gene type that possible strengthen expression below with the compositions and methods of the invention; Development gene (adhesion molecule for example, the cyclin inhibitors of kinases, the Wnt family member, the Pax family member, Winged spiral family member, the Hox family member, cytokine/lymphokine and their receptor, growth or differentiation factor and their receptor, neurotransmitter and their receptor), oncogene (ABLI for example, BLC1, BCL6, CBFA1, CBL, CSFIR, ERBA, ERBB, EBRB2, ETS1, ETV6, FGR, FOX, FYN, HCR, HRAS, JUN, KRAS, LCK, LYN, MDM2, MLL, MYB, MYC, MYCL1, MYCN, NRAS, PIM1, PML, RET, SRC, TAL1, TCL3 and YES), tumor suppressor gene (APC for example, BRCA1, BRCA2, MADH4, MCC, NF1, NF2, RB1, TP53 and W1), (for example ACP desaturase and hydroxylation are quick for enzyme, the ADP-glucose pyrophosphorylase, the ATP enzyme, alcoholdehydrogenase, amylase, amyloglucosidase, catalase, cellulase, cyclo-oxygenase, decarboxylase, dextromase, esterase, DNA and RNA polymerase, hyaluronic acid synthetase, tilactase, glucanase, glucoseoxidase, the 6TP enzyme, unwindase, hemicellulase, hyaluronidase, intergrase, invertase, isomerase, kinases, Lactose enzyme, lipase, lipoxygenase, lyases, lysozyme, pectinesterase, peroxidase, phosphatase, phospholipase, phosphorylase, polygalacturonase, protease and peptidase, amylopectase, recombinase, reverse transcription, topoisomerase, xylanase), and reporter gene (the multiple color variations body of green fluorescent protein matter and it for example, luciferase, the CAT reporting system, beta galactosidase or the like).

The function of tumor suppressor gene is to suppress exhausted cell proliferation.The deactivation of these genes has destroyed their inhibition activity, has caused immoderate propagation.Tumor inhibitor p53, p16 and C-CAM are described below.

Think that at present p53 is a tumor suppressor gene.Having found that high-caliber p53 mutant is present in manyly comprises in the S40 cell transformed through chemical carcinogenesis, ultrasonic emission and multiple virus.The p53 gene usually is the target of sudden change deactivation in various people's tumor, and has proved in the common human cancer gene of the most frequent sudden change.It is undergone mutation in other tumors above (Hollstein etc., 1991) among 50% the people NSCLC and wide model.

A kind of 393-aminoacid of p53 gene code phosphoprotein, energy and host protein, for example big-T antigen and E1b form complex.This protein sees in normal structure and the cell, but compares with transformant or tumor tissues, and concentration is extremely low.Interesting is that wild type-p53 it seems that be important in regulating cell growth and division.The overexpression that has shown wild type-p53 in some cases has anti proliferative in human tumor cell line.Therefore, p53 may play a part the negative regulator (Weinberg, 1991) of cell growth, may directly suppress the gene that sexual cell growth out of control or indirect activation suppress this growth.Therefore, the shortage of wild type-p53 gene or inactivation may cause transforming.Yet some studies show that the existence of p53 mutant may be that this gene transformation potential is expressed necessary fully.

Wild type-p53 is considered to a kind of important growth regulator in many cell types.The sudden change of missense is common in the p53 gene, is that the oncogene conversion capability is necessary.The individual gene change that is caused by point mutation can produce carcinogenecity p53.Yet, do not resemble other oncogene, according to known to the p53 point mutation occur at least in 30 different codons, often produce dominant allele and the change of cell phenotype take place, but can not be reduced to homozygosity.In addition, it seems that many these dominance negative alleles can be tolerated by body and go down to posterity in kind of system.Various mutant alleles seem scope and show the dominance negative allele (Weinberg, 1991) outside intensive from the dysfunction of minimum.

The DNA that Casey and colleagues report encoding wild type-p53 is transfected among two kinds of human breast cancer cell lines, has recovered this cytostatic control (Casey etc., 1991).Proved that also wild type rather than mutant p53 transfection enter the human lung cancer cell line and have similar action (Takahasi etc., 1992).It seems that p53 is better than mutant gene, when with the mutant gene transfectional cell, will select it to resist propagation.The normal expression of transfection p53 can not influence the growth that contains endogenous p53 cell.Therefore, such construction can be absorbed by normal cell and be free from side effects.Therefore, propose to reduce the quantity of malignant cell or reduce their growth rate with wild type p53 treatment p53 associated cancer.

The main transition in eukaryotic cell cycle is subjected to the triggering of the kinases or the CDK of dependent cells cycle regulating protein.A kind of CDK, cyclin dependant kinase 4 (CDK4) is regulated its development by G1.Active receptor 1 activity subunit, D-type cyclin and the inhibition subunit p16 of CDK4 ^INK4Control.P16 ^INK4Through biochemical characteristic be accredited as a kind of can specificity in conjunction with and suppress the protein of CDK4 so the phosphorylation of scalable Rb (Serrano etc., 1993; Serrano etc., 1995).Because p16 ^INK4Albumen is CDK4 inhibitor (Serrano, 1993), and the disappearance of this gene can increase the activity of CDK4, causes the proteinic high phosphorylation of Rb.Know that also P16 can regulate the function of CDK6.

P16 ^INK4Belong to the CDK-repressible protein matter that a class is described recently, also comprise p15 ^INK4B, p21 ^WAF1And p27 ^KIP1P16 ^INK4Gene map is positioned at 9p21, a chromosomal region that often lacks in many tumor types.P16 ^INK4The homozygosity disappearance and the sudden change of gene are common in human tumor cell line.This true prompting p16 ^INK4Gene is a kind of tumor suppressor gene.Yet this explanation has been subjected to challenge, because observe p16 ^INK4Gene is not cultivated change frequency ratio much lower (Caldas etc., 1994 in cultured cells system in the tumor in former generation; Cheng etc., 1994; Hussussian etc., 1994; Kamb etc., 1994; Mori etc., 1994; Okamoto, 1994; Nobori etc., 1995; Orlow etc., 1994; Arap etc., 1995).Yet, in many former generations tumor, be complete though showed the p16 gene afterwards, exist other mechanism to stop p16 protein in the great majority of some tumor types, to be expressed.The hyper-methylation of P16 promoter is (Merlo etc., 1995 in these mechanism; Herman, 1995; Gonzalez-Zulueta, 1995).Recover wild type p16 by the plasmid expression vector transfection ^INK4The function colony that can reduce some cancerous cell lines form (Okamoto, 1994; Arap, 1995).Carry p16 can suppress the propagation of some cancerous cell lines and the growth of reduction people tumor xenogeneic graft with adenovirus vector.

In fact C-CAM has expression (0din and Obrink, 1987) in all epithelial cells.C-CAM, apparent molecular weight 105kD, by with energy in and the specific antibody of cell agglutination reaction (Obrink, 1991) initial separation from the cytoplasmic membrane of rats'liver cell.Recent studies show that structurally, C-CAM belongs to immunoglobulin (Ig) superfamily, its sequence and carcinoembryonic antigen (CEA) height homology (Lin and Guidotti, 1989).Adopt baculovirus expression system (Cheung etc., 1993) to show that the Ig zone of C-CAM is that cell adhesion activity is vital.

Known cell adhesion molecule, or CAM ' s participates in the complex network of intermolecular interaction, and this network adjustment organ is sent out clothing and cell differentiation (Edelman, 1985).Nearest data show that the unconventionality expression of CAM ' s may participate in the generating process of several tumors; For example, the reduction of the E-cadherin expression of mainly expressing in epithelial cell is with development relevant (Edelman and Crossin, 1991 of several tumors; Frixen etc., 1991; Bussemakers etc., 1992; Matsura etc., 1992; Umbas etc., 1992).Equally, (Giancotti and Ruoslahti, 1990) prove that improving α 5 β 1 by gene transfer in the body integrates the tumor generation that plain expression can reduce Chinese hamster ovary cell.Proved that now C-CAM can suppress external and intravital tumor growth.

Relevant (MDA) gene of melanoma differentiation is relevant with differentiation with the human melanoma cell growth, or directly influences their (Su etc., 1998).Recently the tumor promotion that resist-causes that studies have shown that the MDA family member is not limited to melanoma.The expression inhibiting of MDA-7 the growth of external glioblastoma, osteosarcoma, colorectal cancer, breast carcinoma, cervical cancer and nasopharyngeal carcinoma (Jiang etc., 1996).The expression of MDA-7 transfers the effect of dying to suppress the growth of vitro human breast cancer cell and the growth (Su etc., 1998) of the interior xenograft models of body by inducing.

Other adoptable tumor inhibitors of the present invention comprise BRCA1, BRCA2, zac1, p73, MMAC-1, ATM, HIC-1, DPC-4, FHIT, NF2, APC, DDC, PTEN, ING1, NOEY1, NOEY2, PML, OVCA1, MADR2, WT1,53BP2 and IRF-1.

Other adoptable genes of the present invention comprise Rb, APC, DCC, NF-1, NF-2, WT-1, MEN-I, MEN-II, zac1, p73, VHL, MMAC1/PTEN, DBCCR-1, FCC, rsk-3, p27, the p27/p16 fusions, the p21/p27 fusions, antithrombotic forms gene (COX-1 for example, TFPI), PGS, Dp, E2F, ras, myc, neu, raf, erb, fms, trk, ret, gsp, hst, abl, E1A, p300 participates in the gene that blood vessel takes place (VEGF for example, FGF, thrombospondin, BAI-1, GDAIF or their receptor) and MCC.

4. hyaluronic acid

Hyaluronic acid has numerous characteristics, and they may be favourable in other therapeutic treatments and bioprocess.In fact, hyaluronidase is general in treatment and other application of disease, infection.The scope of these application is from simple lubricated, to the conveying of medicine, to the treatment of retrovirus infection.For example see United States Patent (USP) the 6th, 194, No. 392, the 6th, 218, No. 373, the 6th, 271, No. 216, the 4th, 840, No. 941.See Hoekstra equally, (1999) and Lee and Spicer, (2000).

Hyaluronic acid, hyaluronan or hyaluronic acid are a kind of natural polysaccharides (glycosaminoglycan) that exists, and are formed by the repetitive that β 1-3 glycosidic bond is connected with N-acetyl-glucamine by glucuronic acid.These unit are connected to form by β 1-4 glycosidic bond does not have ramose strand.This chain negative charge when the carboxyl ionization of glucuronic acid.It occurs in and produces hyaluronate sodium under the physiology pH value.Hyaluronic acid is good at maintenance moisture very much.

Hyaluronic molecular weight is can be different with concentration in the eye vitreous, depends on the body species that it exists, hyaluronic position in the eyes, and the method for analyzing molecules amount.Therefore, hyaluronic molecular weight can be from 50, and 000Da is above different, and it can form full-bodied solution.It is one of the abundantest chemical compound of human body, is generally used in the extracellular matrix to support and the protection cell.It is present in all body fluid, but at the vitreous humor of eyes, many especially in synovia and the umbilical cord.Hyaluronic acid is a hydrophilic and very lubricated.

The Merck index has determined that hyaluronic molecular weight is 50,000 to 8 * 10 ⁶Within dalton (Da) scope, depend on source, preparation method and assay method.The Merck publication is lectured hyaluronic acid and is a kind of adminicle of external coat.United States Patent (USP) the 4th, 801, having disclosed the hyaluronan molecule amount that intraarticular gives for No. 619 approximately is 3 * 10 ⁶Da or higher.

Hyaluronic acid is separable in the culture of vertebrates tissue (for example people's umbilical cord, rooster comb) or generation bacterial strain.Various other hyaluronic acids of level can be from commercial acquisition.For example see the hyaluronic acid catalogue entry of Sigma.A kind of high-purity, non-inflammatory formal description be in United States Patent (USP) the 4th, 141, No. 973.A kind of commercial product, Healon ^TMCan be from Pharmacia AB (Uppsala, Sweden) acquisition.Hyaluronic acid in this preparation it is said that molecular weight surpasses 750, and (can further surpass 1,200,000Da), and proposition can be applicable to the treatment of various joints situation to 000Da.

There is many hyaluronic acids manufacturer in the whole world.These comprise Anika (Woburn, MA), Biomatrix Inc. (Ridgefield, NJ), Bio-Technology General Corp. (IselinNJ), and Fidia AdvancedBiopolymers (Brindisi, Italy), Genzyme Corp. (FraminghamMA), Kibun Food ChemifaCo. (Tokyo, Japan), Lifecore Biomedical (Chaska, MN) and Seikagaku Corp. (Tokyo, Japan).

The hyaluronic low-molecular-weight precursor of high molecular polymerization natural synthetic thought to be produced by hyalocyte.High-molecular weight hyaluronic acid is formed at ECS, in most cases is the effect by hyaluronic acid synthetase.Exist multiple hyaluronic acid synthetase, can be used for producing hyaluronic acid (Spicer and Mcdonald, 1998) from the low-molecular-weight precursor to the high molecular form.The activity of hyaluronic acid synthetase can be easy to measure (Spicer, 2001).

High molecular weight hyaluronic acid can be handled with enzyme, causes reclaiming its derivant or low-molecular-weight form by hyaluronidase or lyases (EC4.2.2.1).See United States Patent (USP) the 6th, 258, No. 791.Hyaluronidase summary see Kreil (Protein Sci, 1995,4:1666-1669).Hyaluronidase can be from mammal, reptile or hymenopteran hyaluronic acid polysaccharide hydrolytic enzyme, hyaluronic acid polysaccharide hydrolytic enzyme from the Hirudo salivary gland, or from antibacterial, particularly streptococcus, streptococcus pneumoniae and clostruidium hyaluronate lyase.Hyaluronidase extensively obtains from commercial supplier.For example see the hyaluronidase clauses and subclauses (2002) among the Sigma-Aldrich.

5. regulate adenovirus mediated gene expression and the application in adenovirus infection with hyaluronic acid or vitreous body

The inventor has obtained discovery wondrous and beyond expectation, the derivant of high molecular weight hyaluronic acid is a low-molecular-weight hyaluronic acid, " out of date " high molecular weight hyaluronic acid, high molecular weight hyaluronic acid with lyases or hyaluronidase processing, or, can significantly suppress the cell transduction of adenovirus and adenovirus vector through such vitreous body of handling.The unexpected characteristic of these compositionss makes it possible to treat adenovirus infection, the transduction of the infection of replication activity adenovirus vector and adjusting adenovirus vector.

Low-molecular-weight hyaluronic acid is considered among positive the present invention, comprises the product of the high molecular weight hyaluronic acid of contacted energy degraded macromolecular amount form or vitreous body environment.This degraded can be handled or realizes by the hyaluronic acid or the sufficiently long time of vitreous body ingress of air that make the high molecular form by enzyme, perhaps selects than clinical practice permission more aged hyaluronic acid of date or vitreous body.This catabolite can be discerned by analyze complete, unmodified or the fresh hyaluronic acid and the comparison of catabolite with gel electrophoresis method.

Specifically, a kind of limiting examples of this comparison comprises the electrophoresis that carries out associated sample, 0.5% agarose (TAE sees Sambrook 2001) of joining by 1X Tris acetic acid edta buffer liquid.Sample can be added in the hole of agarose gel, join (2M sucrose in the 8x sample loading buffer of 1 volume with 7 volume sample; 1.5M NaCl) and be exposed to the 80-100 volt 4-6 hour.Behind the electrophoresis, the 0.005%StainsAll that joins with 50% ethanol in the dark ^TM(4,5,4 ', 5 '-hexichol-3,3 '-diethyl-9-methyl-thiono cyanogen bromide; 3,3'-diethyl-9-methyl-4,5,4 ', 5 '-hexichol thiono cyanogen; 1-ethyl-2-[3-(3-ethylnaphthalene [1,2-d] thiazoline-2-alkenylene)-2-first acrylic] naphthalene [1,2-d] thiazole  bromide, Sigma-Adrich Co. Inc.) handled 12 hours or spends the night.Then water cleans gel and removes not combination dye.Can manifest hyaluronic acid in 30 minutes by the gel exposure that will handle like this.As what arrive known to these those skilled in the art, the molecular weight of other more transparent matter acid enzyme samples and the method for other characteristics are that these those skilled in the art know, can be used in the context of the present invention, can effectively suppress the sample of adenovirus infection or adenovirus vector-mediated transgene expression to identify those.

Specifically, the inventor provides the method for screening suitable hyaluronidase sample here, as the inhibitor or the reinforcing agent of adenovirus infection or adenovirus mediated transgene expression.Therefore, can screen high molecular weight hyaluronic acid, or contact or high molecular weight hyaluronic acid of handling thereby the sample that has produced low-molecular-weight hyaluronic acid or other derivant, the ability of adenovirus mediated transgene expression of their inhibition or adenovirus infection.Carry out this screening process normally by with this sample and known for adenovirus mediated transgene expression or infect effective composition and make comparisons, the known valid compositions will provide in this description and embodiment.

A kind of typical case but non--restrictive embodiment comprise make the compositions that contains sample with suspicion and adenovirus vector or adenovirus transduction or by the cells contacting of adenovirus infection, make equally contain known to adenovirus mediated transgene expression or infect effective sample (as high molecular weight hyaluronic acid provided herein or vitreous body) and identical cells contacting.Relatively the effect that contacts with described sample can adopt some available methods to measure the method for infectivity, transduction rate or gene expression dose.The inhibition of adenovirus infection or transgene expression can show by the decline of infection or gene expression dose in the suspection sample.Equally, the ability that can working sample strengthens transgene expression.

The level of transgene expression can be measured for example antibody, enzyme test or the like by the method that the related concrete transgenic of specific assay exists.

In specific embodiments, the treatment of adenovirus infection comprises with the adenovirus inhibitor of capacity handles cell, tissue, organ or each body, thereby suppresses the infection of existence, and protecting from infection is diffused into other cell, or prevents the primary infection of any cell.Described inhibitor can comprise derivatives of hyaluronic acids, low-molecular-weight hyaluronic acid, " out of date " hyaluronic acid, " out of date " vitreous body or the vitreous body handled through hyaluronidase or the like.

Described cell and contacting of low-molecular-weight hyaluronic acid or high-molecular weight hyaluronic acid or vitreous body derivant can occur in after a period of time after cell and carrier or virus contact, because cell contacts with carrier or virus earlier, or basically with the cell infection while.Can be after cell and carrier or virus contacts through after a while, make time range that cell and low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or Vitrea derivant contact can from several seconds extremely several minutes to a few hours.Therefore, institute's elapsed time can be 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,41,42,43,44,45,46,47,48,49,50,51,52,53,54,56,57,58,59 or 60 seconds or still less.Similar, institute's elapsed time can be 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,41,42,43,44,45,46,47,48,49,50,51,52,53,54,56,57,58,59 or 60 minute or still less.Equally, institute's elapsed time can be 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23 or 24 hour, and any time scope that can therefrom reason out.

The scope of cell and low-molecular-weight hyaluronic acid or high-molecular weight hyaluronic acid or vitreous body derivant time of contact can be from a few minutes or still less to a few hours or longer.Therefore, the time of described cells contacting can be 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,41,42,43,44,45,46,47,48,49,50,51,52,53,54,56,57,58,59 or 60 seconds or still less.Similar, can be 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,41,42,43,44,45,46,47,48,49,50,51,52,53,54,56,57,58,59 or 60 minute or still less during this period of time.Equally, can be 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24 hour or longer this time of contact, and any time scope that can therefrom reason out.Can be one day perhaps many days the time of contact of special consideration cell and low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant.

The concentration range of applied low-molecular-weight hyaluronic acid or high-molecular weight hyaluronic acid or vitreous body derivant can from less than 10 μ g/100ml at least 240 μ g/100ml or higher.Therefore, amount in the per 100 μ l solution of low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant can be 5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,41,42,43,44,45,46,47,48,49,50,51,52,53,54,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,110,120,150,200,240 μ g or higher, and any concentration range that can therefrom reason out.

Obviously, when purpose was the infection of treatment adenovirus infection or the generation of replication activity adenovirus vector, the time of the concrete time of described treatment and treatment beginning will be by suitable medical practice and experience decision.

In order to strengthen the effectiveness of low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant, it is desirable to these compositionss of the present invention and method and other disease of treatment and the effective preparation coupling of disease.In some embodiments, consideration can be with the treatment of routine or preparation including, but not limited to rem, surgical intervention medicine (for example surgical operation) or their associating, and gives the associating of low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant.Therefore, in certain embodiments, Therapeutic Method of the present invention can comprise that associating other treatment medicine gives low-molecular-weight hyaluronic acid of the present invention or high molecular weight hyaluronic acid or vitreous body derivant.

This process comprises cell is contacted with certain medicine and low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant simultaneously, perhaps in a period of time, give cell, tissue or body with low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant and certain medicine respectively, thereby produce ideal therapeutic effect.Term " contact " and " exposure " when being used for cell, tissue or body, are used for describing the process that therapeutic construction or medicine flow to target cell, tissue or body, or with them and the direct juxtaposed process of target cell, tissue or body.Can make cell, tissue or body (for example by administration) and a kind of compositions or, contain the pharmaceutical preparation contact of low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant and one or more medicines, or by making the contact of cell compositions different or preparation with two or more, wherein a kind of compositions comprises low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant, and other compositions comprises one or more medicines.

Low-molecular-weight hyaluronic acid or high-molecular weight hyaluronic acid or vitreous body derivant can be before other drugs, simultaneously and/or administration afterwards, a few minutes to several weeks at interval.Be applied to respectively in the embodiment of cell, tissue or body in low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant and other drug, usually should guarantee can be obviously not expired between each the conveying, and low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant and medicine still can pair cells like this, tissue or body bring into play favourable synergy.For example, in such example, consider that one can make cell, tissue or body, contact two, three basically simultaneously, four kind or more kinds of medicine (for example in), with low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant less than 1 minute.In other respects, the administration time of one or more medicines from basic with up to about 1 clock, about 5 clocks, about 10 minutes, about 20 minutes, about 30 minutes, about 45 minutes, about 60 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 25 hours, about 26 hours, about 27 hours, about 28 hours, about 29 hours, about 30 hours, about 31 hours, about 32 hours, about 33 hours, about 34 hours, about 35 hours, about 36 hours, about 37 hours, about 38 hours, about 39 hours, about 40 hours, about 41 hours, about 42 hours, about 43 hours, about 44 hours, about 45 hours, about 46 hours, about 47 hours, about 48 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, about 21 days, about 1 day, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months or about 12 months, with can be from any time scope that it is reasoned out, before giving low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant and/or afterwards.

Can adopt the conjoint therapy of multiple low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant and one or more medicines.The non-limitative example of this associating shows below, and the compositions that wherein comprises low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant is " A ", and medicine is " B ":

A/B/A B/A/B B/B/A A/A/B A/B/B B/A/A A/B/B/B?B/A/B/B

B/B/B/A?B/B/A/B?A/A/B/B?A/B/A/B?A/B/B/A?B/B/A/A

B/A/B/A?B/A/A/B?A/A/A/B?B/A/A/A?A/B/A/A?A/A/B/A

To comprise low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid or vitreous body derivant and give the general scheme that cell, tissue or body can be followed the treatment administration, will consider toxicity if any.But estimate the repetitive therapy cycle if desired.In specific embodiments, consider multiple other drug can with use in conjunction of the present invention.

The compositions of regulating transgene expression comprises the hyaluronic acid or the vitreous body solution of various associatings.Hyaluronic acid or vitreous body can with various media compatibility combinatorial input cells, the tissue or the like.These media include but not limited to serum-free cell culture medium and water.The embodiment of being considered comprises other any suitable diluents or media compatible with hyaluronic acid, or other medium or diluent compatible with vitreous body.As described below, this compositions can comprise because other compositions that various purposes add, and as long as antiseptic or the like for example is the effect of the active component that they do not damage wherein to be provided.

The inventor has obtained discovery high molecular weight hyaluronic acid wondrous and beyond expectation or glass physical ability and has obviously strengthened the genetically modified expression that adenovirus and adenovirus vector import.The feasible gene that can regulate adenovirus and the importing of adenovirus relevant carriers of the characteristic of not expecting of these compositionss.In specific embodiments, cell contacts with high molecular weight hyaluronic acid or vitreous body, has strengthened the genetically modified expression of adenovirus like this.

Cell contacts with high molecular weight hyaluronic acid or vitreous body and can occur in cell and carrier or virus contact after a period of time because cell earlier with carrier or viral the contact, or basically with the cell transduction while.Cell and carrier or virus contacts after after a period of time, and cell is contacted with high molecular weight hyaluronic acid or vitreous body, and this time range can be from extremely several minutes or to a few hours several seconds.Therefore, can be 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,41,42,43,44,45,46,47,48,49,50,51,52,53,54,56,57,58,59 or 60 seconds or still less during this period of time.Similar, can be 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,41,42,43,44,45,46,47,48,49,50,51,52,53,54,56,57,58,59 or 60 minute or still less during this period of time.Equally, can be 1,2,3,4,5,6,7,8,9 or 10 hour during this period of time, and any time scope that can therefrom reason out.

The time that cell contacts with high molecular weight hyaluronic acid or vitreous body can be from a few minutes or still less to several hrs or more.Therefore, can be 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,41,42,43,44,45,46,47,48,49,50,51,52,53,54,56,57,58,59 or 60 seconds or still less the time of contact of cell.Similar, can be 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,41,42,43,44,45,46,47,48,49,50,51,52,53,54,56,57,58,59 or 60 minute or still less during this period of time.Equally, can be 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24 hour or longer during this period of time, and any time scope that can therefrom reason out.

The applied concentration range of high molecular weight hyaluronic acid or vitreous body from less than 10 μ g/100ml at least 100 μ g/100ml or higher.Therefore, high molecular weight hyaluronic acid or the vitreous body content in every 100ml solution can be 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,41,42,43,44,45,46,47,48,49,50,51,52,53,54,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100 μ g or higher.Similar, these concentration can be expressed as percent, weight/volume.

The compositions of regulating transgene expression comprises the high molecular weight hyaluronic acid or the vitreous body solution of various combinations.When high molecular weight hyaluronic acid or vitreous body and the combination of various media compatibility provide, they can be imported cell, tissue or the like.Include but not limited to serum-free cell culture medium and water.The embodiment of considering comprises other any suitable diluents or media compatible with hyaluronic acid, perhaps other medium or diluent compatible with vitreous body.As described below, such compositions can comprise other compositions that add for various purposes, and antiseptic etc. for example is not as long as the effect of the active component that wherein provides is provided for they.

6. pharmaceutical preparation

The method of rem and administration, to be that these those skilled in the art are known (for example see dosage or the like, " Physicians Desk Reference ", " the The Pharmacological Basisof Therapeutics " of Goodman and Gilman, " Remington ' s Pharmaceutical Sciences " and " The Merk Index; the 11st edition ", it is for referencial use that this paper includes relevant portion in), can combine according to content disclosed herein and the present invention.Some dosage change and will be inevitable, and this depends on person's to be treated situation.In any case the people who is responsible for administration will determine each patient's suitable dose, determining of this individual dose is within the technical scope of this specialty those of ordinary skill.

Pharmaceutical composition of the present invention only comprises the hyaluronic acid or the vitreous body of effective dose, or the other drug (for example, adenovirus vector) that exists dissolves or is dispersed in the pharmaceutically acceptable carrier.Phrase " medicine or pharmaceutically acceptable " refers to molecular entity and the compositions that can not produce side reaction, allergy or other untoward reaction, when they give animal for example the mankind be suitable.Comprising the content that the preparation of drug combination of at least a adenovirus vector, hyaluronic acid, vitreous body or other active component discloses according to the present invention is that those technical staff of this specialty know, example is seen Remington ' s Pharmaceutical Sciences, the 18th edition, Mack PrintingCompany, 1990.And, for animal (for example people) administration, should be understood that described preparation should meet desired aseptic, the pyrogenicity of FDA authorities biologic criteria, overall safety and purified standard.

As used herein, " pharmaceutically acceptable carrier " comprises any He all solvents, disperse medium, coating materials, surfactant, antioxidant, antiseptic (antibacterial for example, antifungal), isotonic agent, the absorption delay agent, salt, antiseptic, medicine, the medicine stabilizing agent, gel, binding agent, excipient, disintegrating agent, lubricant, sweeting agent, flavoring agent, similar substance and their combinations such as dyestuff, as (seeing known to this specialty those of ordinary skill, Remington ' s Pharmaceutical Sciences for example, the 18th edition, Mack Printing Company, 1990, the 1289-1329 page or leaf).Except so far with the inconsistent any conventional carrier of this active component, all consider its application in therapeutic and pharmaceutical composition.

Compositions of the present invention can comprise dissimilar carriers, depends on that it is with solid, liquid or aerosol form administration, and route of administration whether it needs aseptic as when injection.Route of administration of the present invention can be an intravenous, Intradermal, intra-arterial, intraperitoneal, in sick the damage, intracranial, intraarticular, in the prostate, in the pleura, in the trachea, nasal cavity, in the vitreous body, intravaginal, internal rectum, local, in the tumor, intramuscular, intraperitoneal, subcutaneous, under the conjunctiva, in the capsule, mucosa, in the pericardium, in the umbilical cord, ophthalmic, oral, local, suck (for example aerosol suction), injection, instil, continuous drip, the direct shower target cell of regional perfusion, pass through intubate, lavation, with Emulsion, with lipid composition (for example liposome), or the combination by additive method or said method, as known to this field those of ordinary skill, (see, Remington ' s Pharmaceutical Sciences for example, the 18th edition, MackPrinting Company, 1990).

The actual dose that gives the animal patient present composition can be determined by physics and physiologic factor, for example the type of body weight, severity of disease, disease to be treated, previous or treatment intervention, patient's idopathy and the approach of administration simultaneously.In any case the doctor who is responsible for administration will determine the concentration of active component in the compositions, and suitable dose that should individuality.

In certain embodiments, pharmaceutical composition can comprise, for example at least 0.1% reactive compound.In other embodiments, each administration can contain the about 2%-75% unit of weight of reactive compound, perhaps greatly between 25%-60%, and any scope that can therefrom reason out.In other limiting examples, a dosage can contain about 1 microgram/kg/ body weight, about 5 micrograms/kg/ body weight, about 10 micrograms/kg/ body weight, about 50 micrograms/kg/ body weight, about 100 micrograms/kg/ body weight, about 200 micrograms/kg/ body weight, about 350 micrograms/kg/ body weight, about 500 micrograms/kg/ body weight, about 1mg/kg/ body weight, about 5mg/kg/ body weight, about 10mg/kg/ body weight, about 50mg/kg/ body weight, about 100mg/kg/ body weight, about 200mg/kg/ body weight, about 350mg/kg/ body weight, about 500mg/kg/ body weight, to about 1000mg/kg/ body weight or higher, and any scope that can therefrom reason out.In non-limiting instance, be that approximately the 5mg/kg/ body weight is to approximately 100mg/kg/ body weight, about 5 micrograms/kg/ body weight can be according to above-described quantity administrations to about 500mg/kg/ body weight or the like from the deutero-administration scope of the quantity of listing here.

Under any circumstance, described compositions can contain various antioxidants to delay the oxidation of one or more compositions.In addition, the prevention of microbial action can be by using antiseptic, for example various antibiotic and antifungal include but not limited to p-hydroxybenzoic acid esters (for example methyl metagin, propyl group metagin), chlorobutanol, phenol, sorbic acid, thimerosal or their combination.

Hyaluronic acid of the present invention can be formulated in the compositions of free alkali, neutrality or salt form.Pharmaceutically acceptable salt comprises acid-addition salts, for example the free amino group of those and protein compositions forms, or forms with mineral acid (for example hydrochloric acid or phosphoric acid), or the salt that forms with organic acid (as acetic acid, oxalic acid, tartaric acid or mandelic acid).The salt that forms with free carboxyl group also can be derived from inorganic base, for example sodium, potassium, ammonium, calcium or iron hydroxide; Or organic base such as isopropylamine, Trimethylamine, histamine or procaine.

In described compositions is in the embodiment of liquid form, carrier can be a kind of solvent or disperse medium, including but not limited to water, ethanol, polyhydric alcohol (for example glycerol, propylene glycol, liquid polyethylene glycol or the like), lipid (for example triglyceride, vegetable oil, liposome) and their combination.Keeping suitable flowability can be by using coating, for example lecithin; By being dispersed in carrier for example in liquid polyol or the lipid, keep required particle size; By application surface activating agent, for example hydroxypropyl cellulose; Or the associating of these methods.In many cases, preferably comprise isotonic agent, for example sugar, sodium chloride or their combination.

In other embodiments, can use a dropping liquid, collunarium solution or spraying, aerosol or inhalant in the present invention.It is compatible with the target tissue type that this compositions is typically designed to.In limiting examples, collunarium solution is aqueous solution normally, is designed to be applied to nasal meatus with dropping liquid or spraying.Collunarium solution should be prepared, and becomes similar to nasal discharge in many aspects, can keep normal ciliary movement like this.Therefore, in preferred embodiments, aqueous collunarium solution is normally isoosmotic or slight buffered to keep the pH value of about 5.5-6.5.In addition, be applied to antibiotic antiseptic similar in the ophthalmic preparation with those, medicine or suitable medicine stabilizing agent also can be included in the described preparation if desired.For example, the extensive stock intranasal formulation is known, includes such as medicines such as antibiotic or antihistamine.

In certain embodiments, but the present composition by oral route administration of preparation.In these embodiments, described solid composite can comprise, for example solution, suspension, Emulsion, tablet, pill, capsule (for example hard or soft gelatin shell capsule), sustained release formulation is sucked agent compositions, tablet, lozenge, elixir, suspension, syrup, wafer or their combination.Orally administered composition can directly mix the food in the meals.The preferred carrier of oral administration comprises inert diluent, can assimilate edible carrier or their combination.Other aspects of the present invention can be formulated as oral compositions syrup or elixir.Syrup or elixir also can comprise for example at least a active medicine, sweetener, antiseptic, flavoring agent, dyestuff, antiseptic or their combination.

In certain preferred aspects, Orally administered composition can comprise one or more binding agents, excipient, disintegrating agent, lubricant, flavoring agent and their combination.In certain embodiments, compositions can comprise one or more following materials: binding agent is tragakanta, acacia, corn starch, gelatin or their combination for example; Excipient is dicalcium phosphate, mannitol, lactose, starch, magnesium stearate, saccharin sodium, cellulose, magnesium carbonate or their combination for example; Disintegrating agent is corn starch, potato starch, alginic acid or their combination for example; Lubricant, for example magnesium stearate; Sweetener, for example sucrose, lactose, glucide or their combination; Flavoring agent is Herba Menthae, wintergreen oil, Fructus Pruni pseudocerasi flavoring agent, orange flavoring agent or the like for example; Or above-mentioned combination.When dosage unit form is capsule, except the material of the above-mentioned type, also can comprise carrier, for example the liquid carrier.Other multiple materials can coating form have or the physical form of modifying described dosage unit.For example, tablet, pill or capsule can be used Lac, sugar or both parcels.

The preparation that is fit to other administering modes comprises suppository.Suppository is the solid dosage form of multiple weight and shape, adds medicine usually, inserts rectum, vagina or urethra.After inserting, suppository deliquescing in coelomic fluid, thawing or dissolving.For suppository, traditional carrier comprises for example ployalkylene glycol, triglyceride or their combination usually.In certain embodiments, suppository can the mixture of active component forms by for example containing, and the scope of active component is about 0.5%-10%, preferably approximately 1%-2%.

The preparation of aseptic injectable solution is to join in the suitable solvent by the reactive compound with aequum, and this solvent contains above various other compositions of enumerating, subsequent filtration degerming if desired.Usually, dispersion liquid is to prepare by various sterile active compositions are joined in the aseptic carrier that contains basic dispersion medium and/or other compositions.Preparing with sterilized powder in the situation of sterile injectable solution, suspension or Emulsion, the method for optimizing of preparation is vacuum drying or Freeze Drying Technique, can produce active component and add powder from other required compositions of liquid medium after the aseptic filtration of front.This liquid medium should suitably cushion if desired, makes this liquid diluting liquid etc. ooze earlier with enough saline or glucose before injection.Also consider the high concentration composition of preparation as direct injection, anticipation can cause infiltration very fast as solvent wherein to adopt DMSO, with zonule of active medicine input of high concentration.

United States Patent (USP) the 4th, 808, pointed out hyaluronic acid No. 576, a kind of well-known preparation that when directly applying to wounded tissue, can reduce wound final result in the mammal joint tissue, if it is applied to position away from wounded tissue, it will be transported to this wounded tissue by mammiferous natural process.Therefore, according to this patent, can any treatment on acceptable form give hyaluronic acid by common away from approach, comprise intravenous, intramuscular, subcutaneous and local.This specific character makes hyaluronic application greatly convenient and attractive.For example, with hyaluronic acid treatment horse or person joint when scorching, no longer need more intra-articular injection according to this patent because of difficulty.

Make and storage condition under, described compositions must be stable, and can be protected and be not subjected to for example pollution of antibacterial and fungus of microorganism.Should know that contaminated with endotoxins should keep minimum, in the level of safety, for example is lower than 0.5ng/mg protein.

In specific embodiments, can Injectable composition be prolonged and absorb for example collagen, aluminum monostearate, gelatin or their combination.

Embodiment

The following examples comprise the demonstration preferred embodiment of the invention.Those skilled in the art should know disclosed technology among the embodiment, have followed the representative art that the inventor finds, go on well in the embodiment of this invention, therefore can think to have constituted enforcement optimal way of the present invention.Yet those technicians of this area according to content disclosed herein, will be appreciated that and can do many variations in disclosed specific embodiments, still can obtain same or similar result, and not deviate from thinking of the present invention and scope.

Material that adopts among the embodiment 1-5 and methodology

Cell line

With WERI-Rb cell (from human retinoblastoma), Jurkat cell (the acute T-cell lymphoma of people), through genetic engineering modified and can express CD44, and HeLa cell (dermoid cancer on the human cervical cancer 1) is kept in the culture medium, adopt the Minimal Essential culture medium of having added 5%FCS.By (using CellFECTIN with the plasmid transfection that contains CD44 minigene (Brian Seed, Harvard University) ^TM, GibcoBRL) the Jurkat cell is set up Jurka-CD44 cell line.After 72 hours, use G418 (800 μ g/ml) selection to express the cell of CD44, and set up stable cell line by the dilution clone.(by L.Huber, IMP, the mouse epithelial cell that Vienna, Austria provide) is incubated in Dulbeco ' the s MinimalEssential culture medium that is added with 10%FBS and glucose (4.5g/l) with the EpH4 cell.Can show that serum has effect for adenovirus mediated transgene expression, yet this effect is strong not as vitreous body, the effect of serum is not subjected to the inhibition of lyases digestion yet.Here Bao Dao experiment is to carry out with the cell that is incubated at serum-free or 0.5% serum, to differentiate Vitrea effect.The all cells culture maintains 37 ℃ 5% CO ₂In.

The adenovirus construction thing

Adenovirus 5 (AdV) construction that contains LUC Photinus pyralis LUC Photinus pyralis FL (AdV-Iuc) or green fluorescent protein matter (AdV-GFP) reporter gene or express adenovirus 35 (AdV5/F35) fibre structure territory is provided by the cell and the gene therapy center of Baylor medical college.The construction of expressing sudden change fiber/ball-joint or penton base structure territory provides (Gen Vec Corp) by T.Wickham.

Antibody and reagent

The KM114 monoclonal antibody of the hyaluronic acid enzyme binding site of anti-mice CD44 is available from BD BiosciencesPharMingen.Vitreous body can from fresh or refrigerated bovine eye, gather in the crops (Ladpak Slaughterhouse, Needville, TX).Shear vitreous body with the 19-syringe needle and reduce its viscosity, centrifugal clarification dilutes with serum-free medium then.Hyaluronate lyase and collagenase are from SIGMA ^TMBuy (Sigma-Aldrich Co., Inc.).High molecular weight hyaluronic acid (Healon ^TM, 1% hyaluronate sodium) and available from Pharmacia, Corp.Use the luciferase pilot system ^TM(Promega) uciferase activity of quantitative assay expression.

Embodiment 1: vitreous body strengthens the transgene expression of adenovirus-mediation

When adopting AdV-Iuc, when the adenovirus vector of a kind of reporter gene that contains--firefly luciferase gene was transduceed retinoblastoma cell line, the vitreous body of low concentration had significantly strengthened the transgene expression of adenovirus-mediation.With WERI-Rb cell (1 * 10 ⁴Cells/well) cultivated 18 hours with AdV-Iuc (200 virom crosomes (vp/ cell)) and 0% (contrast), 0.1%, 0.5%, 2.5% and 5% freshly prepared cattle vitreous body.Harvesting is also measured uciferase activity.Culture is divided in triplicate to be tested.Fig. 1 shows that the increase of transgene expression is the direct function of vitreous body concentration.Observed height when there is serum in this enhancing ratio.

Embodiment 2: hyaluronate lyase has been eliminated Vitrea potentiation

In order to investigate Vitrea two kinds of main components: collagen or hyaluronic latent effect digested vitreous body with collagenase or hyaluronate lyase before cultivating with retinoblastoma cell and viral vector.Vitreous body or serum are diluted to 1% with serum-free medium, then handled 1 hour for 37 ℃ with hyaluronate lyase (Streplytica, 10 units).The vitreous body handled or serum are added in WERI-Rb cell (1.2 * 10 in the serum-free medium at serum-free ⁴Cells/well), to ultimate density be 0.5%.Add AdV-luc (500vp/ cell), cultured cell 18 hours.Harvesting is also measured uciferase activity.

With of the enhancing not effect of collagenase digesting vitreous body to reporter gene expression.Yet, eliminated Vitrea effect (Fig. 2) with hyaluronate lyase digestion (10 unit lyases are arranged in the vitreous body of 500 microlitres 1%).Boil the deactivation lyases and can not suppress the enhanced adenovirus mediated luciferase expression of vitreous body (not having video data).

Embodiment 3: strengthen to express not relying on adenovirus combination or internalization

In order to measure combination or the internalization whether vitreous body can strengthen adenovirus, use ³⁵S-methionine mark adenovirus vector then exists or is lacking under the 0.5% Vitrea situation and HeLa cell (known CAR of having and α _vIntegrate element, and easily by adenovirus infection) cultivate together.After the cultivation, washed cell is also measured total radioactivity.After 6 hours, quantitative assay ³⁵S amount does not have difference, and this shows that enhancing does not occur in combination and internalization stage, but at some subsequent steps (not having video data) of transgene expression.

Fiber/ball-joint protein or penton alkaline protein in the adenovirus vector that adopts suddenly change, thereby have strengthened these conclusions.With WERI-Rb cell (1 * 10 ⁴Cells/well) in serum-free medium with prominent different penton of wild-type adenovirus or fiber mutant (1000vp/ cell), when existing or lacking 0.5% vitreous body, cultivated together 18 hours.Harvesting is also measured the activity of luciferase.Adenovirus has reduced the ability that adenovirus enters cell in conjunction with the destruction of (fiber/ball-joint of sudden change) or internalization (the penton base of sudden change) domain, but does not suppress the ability (Fig. 3) that vitreous body strengthens the luciferase transgene expression.

Adenovirus vector with another modification is further confirmed these observations.AdV serum 5 types need be as bonded CAR receptor and the α that is used as internalization _vIntegrate plain; AdV serum 35 types utilize a kind of different mechanism.The GFP that AdV5 (AdV5F35) by the genetic engineering modified AdV35 of containing celloglobulin is entered as the retina cell oncocyte expresses, and has also increased in the presence of 0.5% vitreous body.

With WERI-Rb cell (1 * 10 ⁴Cells/well) in serum-free medium and (C, D) or the discord (A, B) 0.5% vitreous body is cultivated together.With the ratio transducer cell of chimeric adenovirus (AdV5/F35) with the 5vp/ cell, the fiber of AdV35/ball-joint zone has substituted fiber/ball-joint zone of AdV5 in this embedded virus.Shown representative area bright district (A, C) and phosphor region (B, D) figure (Fig. 4).Therefore, if adenovirus can in conjunction with and internalization, no matter vitreous body can strengthen genetically modified expression and used receptor.

Embodiment 4: the time dependence of vitreous body potentiation

WERI-Rb cell and AdV-luc (200vp/ cell) were cultivated 2 hours together feasible viral combination and the internalization of allowing if having time in serum-free medium.Washed cell is resuspended in the fresh serum-free medium, and with 1 * 10 ⁴In the hole of going into 96-hole microtitre flat board of cells/well five equilibrium.Shown in the time add vitreous body, make that ultimate density is 0.5%.Add and carry out luciferase assay after AdV-luc20 hour.If after removing adenovirus, added the maximum enhancing (Fig. 5) that vitreous body can obtain adenovirus-mediation transgene expression at least in 6 hours.

On the contrary, when everybody culture is removed adenovirus, add vitreous body, remove vitreous body by washed cell at interval at different time subsequently then, can strengthen genetically modified expression at least 6 hours.WERI-Rb cell and AdV-luc (200vp/ cell) were cultivated 2 hours together feasible viral combination and the internalization of allowing if having time in serum-free medium.Clean described cell, be resuspended in fresh serum-free medium and add in 0.5% the vitreous body, continue to cultivate.Shown in the time, reclaim cell, washing and with resuspension in the serum-free medium, then with 1 * 10 ⁴Branches such as cells/well add in the hole of 96-hole microtitre flat board.After adding AdV-luc20 hour, carry out luciferase assay (Fig. 6).

Embodiment 5: hyaluronic acid has strengthened adenovirus mediated transgene expression

High molecular weight hyaluronic acid has strengthened the transgene expression that adenovirus is carried.With WERI-Rb cell (1 * 10 ⁴Cells/well) and AdV-luc (200vp/ cell) and concentration (average M.W.650 000kDa) cultivates 18 hours together from the high molecular weight hyaluronic acid of the fresh dilution of 0-100 microgram hyaluronic acid/100 microlitres.Collecting cell is also measured uciferase activity.Culture is divided into three equal parts carries out (Fig. 7).Transgene expression can strengthen up to 20 times.

Embodiment 6: adenovirus mediated transgene expression likes that hyaluronic acid degraded or that modify suppresses

The hyaluronic acid that has been subjected to the limited digestion of lyases not only can not activate, and has in fact suppressed the adenovirus mediated transgene expression of baseline.With WERI-Rb cell (1 * 10 ⁴Cells/well) and " out of date " hyaluronic acid of AdV-luc (200vp/ cell) and concentration 0-240 microgram/100 microlitres cultivated together 18 hours.Collecting cell is also measured uciferase activity.Culture is divided into three equal parts to carry out.Even Fig. 8 shows the cleaved enzymic digestion of part, the hyaluronic acid that also can cause configuration to change, it can effectively suppress adenovirus mediated transgene expression.

Embodiment 7:CD44 participates in the adjusting of adenovirus mediated transgene expression

Because the enhancing of the inductive adenovirus mediated transgene expression of vitreous body can be eliminated by digesting vitreous body with hyaluronate lyase, and can realize by the macromolecule hyaluronic acid of purification, therefore check the latent effect of hyaluronic acid bind receptor CD44.Jurkat and Jurkat-CD44 cell are cultivated activation CD44 with PM (10ng/ml).Washed cell is resuspended in the serum-free medium, and with 1 * 10 ⁴Branches such as cells/well add in the microtitre flat board of 96-hole.Add AdV-luc (1000vp/ cell), cultivated cell 18 hours when measuring uciferase activity then at the hyaluronic acid (100 micrograms/hole) that exists or lack fresh dilution.Jurkat cellular expression CAR but do not express CD44 or other hyaluronic acid bind receptors, also express alpha not _VIntegrate element, be difficult for being transduceed, be not subjected to Vitrea influence the (Fig. 9) by AdV5.Yet, can be transduceed by AdV5 with the Jurkat cell of CD44 expression plasmid stable transfection, and genetically modifiedly can strengthen (Fig. 9) when being expressed in hyaluronic acid and existing.

For the further effect of checking CD44, checked and to have blocked the bonded mice CD44 of hyaluronic acid antibody (KM114), to determine that it is to the enhanced effect of vitreous body.Adopt CD44 to express mouse cell lines EpH4 as target cell.Mice EpH4 cell (the CD44 positive) is cultivated in advance in the serum-free medium of the IgG1 control antibodies that has excessive KM114 (a kind of CD44 monoclonal antibody specific) or homotype-coupling.Washed cell also is resuspended in the serum-free medium, with 1 * 10 ⁴Branches such as cells/well add 96-hole microtitre flat board.Adding AdV-luc (200vp/ cell) also continues cultivation and measured uciferase activity in 18 hours then.Culture is divided into three equal parts to carry out.Vitreous body has strengthened transgene expression (Figure 10) in the presence of homotype coupling control antibodies.When KM114 existed, not only the enhanced transgene expression of vitreous body was suppressed, and the baseline transgene expression also is suppressed (Figure 10).These results have confirmed CD44 and the effect of its part hyaluronic acid in regulating adenovirus mediated transgenic.

Embodiment 8: the screening of hyaluronic acid form

Carry out the electrophoresis of associated sample by 1X Tris acetic acid edta buffer liquid (TAE sees Sambrook 2001) 0.5% agarose of joining.Adopt 7 volume sample to add 1 volume 8x sample loading buffer (2M sucrose; 1.5M NaCl) sample is added in the hole of agarose, and is exposed to 80-100 volt voltage 4-6 hour.Behind the electrophoresis, 0.005% StainsAll that joins with 50% ethanol in the dark ^TM(SIGMA ^TM) treatment gel 12 hours or spend the night, then wash with water and remove not marriage chain.Made hyaluronic acid manifest in 30 minutes the gel exposure of handling.

Carry out in material that working sample provides in the above-described embodiments to the effect of adenovirus mediated transgene expression and the method.That is be that the hyaluronic acid sample of being tried of 0-100 microgram hyaluronic acid/100 microlitres was cultivated 18 hours together with WERI-Rb cell and AdV-luc (200vp/ cell) and concentration.Harvesting is also measured uciferase activity.

Embodiment 9: vitreous body can be repaired low-molecular-weight hyaluronic acid

Figure 12 shows that Vitrea potentiation repaired low-molecular-weight hyaluronic acid.Low-molecular-weight hyaluronic acid and Vitrea synergy are doubled, and cause 1000-times of transgene expression increase nearly.With WERI-Rb cell and AdV-luc (200vp/ cell), and contrast, the vitreous body of fresh dilution, low-molecular-weight hyaluronidase, the vitreous body of associating low-molecular-weight hyaluronic acid with 100 microgram hyaluronic acids/100 microlitres, was cultivated 18 hours together.Harvesting is also measured uciferase activity.

The vignette of Figure 12 has shown the same data with big figure, but its big I shows the inhibitory action that independent potentiation that produces of vitreous body and low-molecular-weight hyaluronic acid produce separately.All are all obviously different with the expression of expressing contrast.

In 100 μ l serum-free mediums, this culture fluid contains 0.5% vitreous body or 100 μ g with 1 hour hyaluronic acid of 10 units lyases digestion as shown with fresh people's conjunctiva place plant cultivation.24, under Laser Scanning Confocal Microscope, check culture after 48 and 72 hours.

Embodiment 10: vitreous body has effectively strengthened expression, and low-molecular-weight hyaluronic acid has effectively suppressed adenovirus mediated transgene expression in the outer plant of people's conjunctiva

Figure 13 has shown that conjunctival tissue is cultivated with vitreous body and has strengthened adenovirus mediated transgene expression in the outer plant of people's conjunctiva.Same demonstration low-molecular-weight hyaluronic acid has suppressed adenovirus mediated transgene expression.Handle vitreous body with lyases and eliminated Vitrea effect.Similar with embodiment 9 results, vitreous body and low-molecular-weight hyaluronic acid are united the several times that cause transgene expression and are strengthened.

Disclosed herein and all compositionss advocated and/or method need not be too much experiment, only can carry out and implement according to the disclosure that is provided.Though the compositions and methods of the invention are described by embodiment preferred, those skilled in the art understand above-mentioned composition and/or method and step, and the order of methods described herein step can change, and do not deviate from notion of the present invention, thinking and scope.More specifically say, obvious some chemistry alternative preparation as herein described of preparation all relevant with physiology, and can obtain same or analogous result.Those skilled in the art understand that all these similar substituting and revise all are considered as within thinking of the present invention, scope and notion, as incidental claim is determined.

List of references

It is for referencial use that following list of references is included this paper in, and they provide program exemplary or other details, as replenishing that this paper provides.

United States Patent (USP) the 4th, 141, No. 973

United States Patent (USP) the 4th, 801, No. 619

United States Patent (USP) the 4th, 808, No. 526

United States Patent (USP) the 4th, 840, No. 941

United States Patent (USP) the 5th, 670, No. 488

United States Patent (USP) the 5th, 824, No. 544

United States Patent (USP) the 5th, 932, No. 210

United States Patent (USP) the 6th, 194, No. 392

United States Patent (USP) the 6th, 218, No. 373

United States Patent (USP) the 6th, 258, No. 791

United States Patent (USP) the 6th, 271, No. 216

Abe etc., Proc.Soc.Exp.Biol.Med., 203:354-359,1993.

Arap etc., Cancer Res., 55 (6): 1351-1354,1995.

Cancer Res. such as Banerjee, 52:6297-6304,1992.

Batra etc., Am.J.Respir.Cell Mol.Biol., 21 (2): 238-45,1999.

Behbakht etc., Am.J.Obstet.Gynecol., 175 (5): 1260-1265,1996.

Bett etc., J.Virol., 67 (10): 5911-5921,1993.

Blackwell etc., Arch.Otolaryngol.Head.Neck Surg., 125 (8) 856-863,1999.

Bussemakers etc., Biochem.Biophys.Res.Commun., 182 (1): 318-324,1992.

Caldas etc., Nat.Genet., 8 (1): 27-32,1994.

Casey etc., Oncogene, 6 (10): 1791-1797,1991.

Chen etc., Proc.Natl.Acad.Sci.USA, 91 (8): 3054-7,1994.

Chen etc., Proc.Natl.Acad.Sci.USA, 92 (7): 2577-2581,1995.

Cheng etc., Cancer Res., 54 (21): 5547-5551,1994.

Cheung etc., J.Biol.Chem., 268 (32): 24303-24310,1993.

Chillon etc., J.Virol., 73 (3): 2537-40,1999.

Chroboczek etc., Virology, 186:280-285,1992.

Dorai etc., Int.J.Cancer, 82 (6): 846-52,1999.

Eastham etc., Hum.Gene Ther., 7 (4): 515-23,1996.

Edelman and Crossin, Annu.Rev.Biochem., 60:155-90,1991.

Edelman，Ann.Rev.Biochem.，54：135-169，1985.

Esandi etc., Gene Ther., 4 (4): 280-7,1997.

Evans.Am.J.Hyg.67：256-263，1958.

Feldman etc., Cardiovasc.Res., 32 (2): 194-207,1996.

Flomenberg etc., J.Infect.Dis., 169:775-781,1994.

Frixen etc., J.Cell.Biol., 113 (1): 173-185,1991.

Giancotti and Ruoslahti, Cell60 (5): 849-859,1990.

Goebel etc., Ann.Otol.Rhinol.Laryngol., 105 (7): 562-7,1996.

Golasten etc., New Engl.J.Med., 309 (11983): 288-296,1983.

Gonzalez-Zulueta etc., Cancer Res., 55 (20): 4531-4535,1995.

Graham and Prevec, Mol Biotechnol., 3 (3): 207-20,1995.

Han etc., Biol.Pharm.Bull., 22 (5): 836-40,1999.

Herman etc., Cancer Res.55 (20): 4525-30,1995.

Hermans and Verhaagen, Prog.Neurobiol., 55 (4): 399-432,1998.

Hoekstra selects from Hyaluronan-modified surfaces for medical devices, MedicalDevice and Diagnostic Industry Magazine, 1999.

Hollstein etc., Science, 253:49-53,1991.

Horwitz selects from Virology, second edition, Fields (volume), Raven Press, Ltd.New York, 1990.

Hurwitz etc., Hum.Gene Ther., 10:411-48,1999.

Hussussion etc., Nat.Genet., 8 (1): 15-21,1994.

Irie etc., Antisense Nucleic Acid Drug Dev., 9 (4): 341-9,1999.

Ishibashi etc., J.Clin.Invest., 92:883-893,1993.

Ishibashi etc., J.Clin.Invest., 93:1885-1893,1994.

Jiang etc., Proc.Nat ' l Acad.Sci.USA, 93:9160-9165,1996.

Kemb etc., Nat.Genet., 8 (1): 23-2,1994.

Klaassen selects from The Pharmacological Basis of Therapeutics, and Goodman and Gilman compile, Pergamon Press, the 8th edition, 49-61 page or leaf, 1990.

Kreil，Protein?Sci.，4(9)：1666-9，1995.

Lee and Spicer, Curr.Opin.Cell Biol., 12,581-586,2000.

Lesch，Biol.Psychiatry，45(3)：247-53，1999.

Claims

1. contain hyaluronic adenovirus inhibitor and be used for the treatment of application in the medicine of patient's adenovirus disease in preparation.

2. application as claimed in claim 1, wherein said adenovirus inhibitor comprises low-molecular-weight hyaluronic acid.

3. application as claimed in claim 2, wherein said hyaluronic mean molecule quantity be less than 750,000Da.

4. application as claimed in claim 2, wherein said hyaluronic mean molecule quantity are 50, and 000Da to 750 is between the 000Da scope.

5. application as claimed in claim 4, wherein said hyaluronic mean molecule quantity are 50, and 000Da to 300 is between the 000Da scope.

6. application as claimed in claim 1, wherein said hyaluronic catabolite of adenovirus inhibitor packages pbz polymer amount or Vitrea catabolite.

7. application as claimed in claim 1, wherein said adenovirus inhibitor are further defined as with lyases or hyaluronidase and handle high molecular weight hyaluronic acid and the product that obtains.

8. application as claimed in claim 1, wherein said patient is the people.

9. the compositions that contains hyaluronic adenovirus inhibitor is used for suppressing the application of the medicine of adenovirus infection in preparation.

10. application as claimed in claim 9, wherein said adenovirus inhibitor comprises low-molecular-weight hyaluronic acid.

11. the regulator that contains hyaluronic adenovirus mediated transgene expression is used for regulating application through the preparation of the transgene expression of the cell of adenovirus or adenovirus vector transduction in preparation.

12. application as claimed in claim 11, wherein said regulator comprises high molecular weight hyaluronic acid or vitreous body.

13. application as claimed in claim 11, wherein said regulator contain the catabolite or the vitreous body catabolite of low-molecular-weight hyaluronic acid or high molecular weight hyaluronic acid.

14. application as claimed in claim 13, wherein said regulator are further defined as with lyases or hyaluronidase and handle high molecular weight hyaluronic acid and the product that obtains.

15. a method of making treatment adenovirus infection medicine is characterized in that this method comprises that acquisition contains hyaluronic adenovirus inhibitor and is mixed with described inhibitor with pharmaceutically acceptable carrier.

16. contain hyaluronic adenovirus mediated transgene expression reinforcing agent in the application of preparation raising in the preparation of the transit cell gene expression of adenovirus vector transduction.

17. application as claimed in claim 16, wherein said reinforcing agent comprises vitreous body.

18. application as claimed in claim 17, the vitreous body concentration in the wherein said compositions is between 0.5%-5% (v/v) scope.

19. application as claimed in claim 16, wherein said reinforcing agent comprises high molecular weight hyaluronic acid.

20. application as claimed in claim 19, hyaluronic concentration is within the scope of 10 micrograms/100 microlitre to 240 micrograms/100 microlitres in the wherein said compositions.

21. application as claimed in claim 20, hyaluronic concentration is within the scope of 10 micrograms/100 microlitre to 100 micrograms/100 microlitres in the wherein said compositions.

22. application as claimed in claim 16, wherein said reinforcing agent contains the mixture of vitreous body and high molecular weight hyaluronic acid.

23. application as claimed in claim 16, wherein said adenovirus vector is derived from adenovirus 5 or adenovirus 2 or adenovirus.

24. application as claimed in claim 16, wherein said carrier are further defined as and comprise transgenic.

25. application as claimed in claim 24, wherein said transgenic can be used for treating cancer.

26. application as claimed in claim 25, wherein said cancer is a retinoblastoma.

27. application as claimed in claim 26, wherein said transgenic are retinoblastoma gene or thymidine kinase gene.

28. application as claimed in claim 24, wherein said transgenic is a tumor suppressor gene.

29. application as claimed in claim 28, wherein said tumor suppressor gene coding p53.

30. application as claimed in claim 24, wherein said transgenes encoding-reporter gene.

31. adenovirus vector and anti-CD44 specific antibody be combined in the application that preparation is used for regulating the preparation of transgene expression.

32. application as claimed in claim 31, described combination also comprises high molecular weight hyaluronic acid or vitreous body.

33. application as claimed in claim 31, wherein said antibody is monoclonal antibody.

34. application as claimed in claim 31, wherein said antibody is KM114.

35. a test kit that improves transgene expression is characterized in that this test kit comprises high-molecular weight hyaluronic acid or vitreous body, and the component that is used for the adenovirus vector transfection.